Background The potential usefulness of adriamycin (ADR) is restricted because of its cardiotoxic side effects. Since free radicals and lipid peroxidation are suggested to be involved in ADR cardiomyopathy, we examined the beneficial effects of probucol, a lipid-lowering drug with strong antioxidant properties.
Probucol Promotes Endogenous Antioxidants
and Provides Protection Against Adriamycin-Induced Cardiomyopathy in Rats N. Siveski-Iliskovic, MD; N. Kaul, PhD; P.K. Singal, PhD Background The potential usefulness of adriamycin (ADR) is restricted because of its cardiotoxic side effects. Since free radicals and lipid peroxidation are suggested to be involved in ADR cardiomyopathy, we examined the beneficial effects of probucol, a lipid-lowering drug with strong antioxidant properties.
Methods and Results ADR was administered to rats in six equal intraperitoneal injections over a period of 2 weeks (cumulative dose of 15 mg/kg). After a 3-week posttreatment period, cardiomyopathy and congestive heart failure were characterized by ascites, congested liver, depressed cardiac function, elevated left ventricular end-diastolic pressure, and myocardial cell damage. Myocardial glutathione peroxidase (GSHPx) activity was decreased, and lipid peroxidation was increased. Probucol (cumulative dose, 60 mg/kg IP) was administered in six equal injections over a 2-week period on days alternating with ADR treatment. Probucol significantly attenuated the myocardial effects of ADR, improved left ventricular function, and lowered mortality as well as the amount of ascites. Treatment with probucol was also accompanied by an increase in myocardial GSHPx and superoxide dismutase activities, with a concomitant decrease in lipid peroxidation.
Conclusions These data provide evidence that ADR cardiomyopathy is associated with an antioxidant deficit. Improved cardiac function resulting from treatment with probucol may be related to the maintenance of the antioxidant status of the heart. The study suggests potential usefulness of antioxidant (probucol) An acute study involving a single injection of adriamycin (15 mg/kg) in mice showed that a single pretreatment with 85 IU of vitamin E provided protection with respect to cardiac cell damage that was also accompanied by a reduction in lipid peroxidation. 15 In the present study, we examined the beneficial effects of repeated treatment with probucol, a lipid-lowering drug with strong antioxidant property, in a chronic model of adriamycin-induced congestive heart failure in rats. In addition, hemodynamic function, myocardial ultrastructure, lipid peroxidation, and various antioxidant enzyme activities were also studied.
Methods

Animal Model
Male Sprague-Dawley rats, body weight 250+10 g, were maintained on a normal rat chow diet. Rats were divided into four groups: CONT (control), ADR 19 Cytosolic GSHPx was assayed in a 3 -mL cuvette containing 2.0 mL of 75 mmol/L phosphate buffer, pH 7.0. The following solutions were then added: 50 ,L of 60 mmol/L glutathione, 100 ,L glutathione reductase solution (30 U/mL), 50 ,L of 0.12 mol/L NaN3, 0.10 of 15 mmol/L Na2EDTA, 100 gtL of 3.0 mmol/L NADPH, and 100 ,uL of cytosolic fraction obtained after centrifugation at 20 000g for 25 minutes. Water was added to make a total volume of 2.9 mL. The reaction was started by the addition of 100 ,uL of 7.5 mmol/L H202, and the conversion of NADPH to NADP was monitored by a continuous recording of the change of absorbance at 340 nm at 1-minute intervals for 5 minutes. Enzyme activity of GSHPx was expressed in terms of milligrams of protein.
Superoxide Dismutase Assay
Supernatant (20 00(g for 20 minutes) was assayed for superoxide dismutase (SOD) activity by following the inhibition of pyrogallol auto-oxidation. 20 Pyrogallol (24 mmol/L) was prepared in 10 mmol/L HCl and kept at 4°C before use. Catalase (30 ,umol/L stock solution) was prepared in an alkaline buffer (pH 9.0). Aliquots of supernatant (150 ,ug protein) were added to Tris HCI buffer containing 25 ,uL pyrogallol and 10 ,uL catalase. The final volume of 3 mL was made up of the same buffer. Changes in absorbance at 420 nm were recorded at 1-minute intervals for 5 minutes. SOD activity was determined from a standard curve of percentage inhibition of pyrogallol auto-oxidation with a known SOD activity. This assay was highly reproducible, and the standard curve was linear up to 250 ,ug protein with a correlation coefficient of 0.998. Data are expressed as SOD units per milligram protein compared with the standard.
Malondialdehyde Assay
Measurement of lipid peroxidation by determination of myocardial malondialdehyde (MDA) content was performed by a modified thiobarbituric acid (TBA) method.21 Hearts were quickly excised and washed in buffered 0.9% KCl (pH 7.4). After the atria, extraneous fat, and connective tissue were removed, the ventricles were homogenized in the same buffer 37°C in a water bath. A 2-mL aliquot was withdrawn from the incubation mixture and pipetted into an 8- 
Results
General Observations and Mortality
The general appearance of all groups of animals was recorded during the time course of the study. After completion of adriamycin treatment, the animals' fur became scruffy and developed a light yellow tinge, and there was red exudate around the eyes in both ADR and PROB+ADR groups, although more extensively in the ADR group. Animals in the ADR group also appeared to be sicker, weaker, and lethargic compared with the PROB+ADR group. The most predominant feature in the ADR group animals was the development of a grossly enlarged abdomen and ascites. This condition became apparent within a week after the completion of treatment with adriamycin. When they were killed, all ADR group animals had a significant amount of peritoneal fluid (Table 1 ). In addition, the liver was enlarged and congested in all ADR group animals. In the PROB+ADR group animals, the amount of peritoneal fluid was about one fifth that seen in animals in the ADR group (Table 1) . During the posttreatment period, the mortality rate was significantly higher in the ADR group than in the PROB+ADR group (Table 1) . (10% wtfvol). The homogenate was incubated for 1 hour at There were no deaths in the CONT and PROB groups. Data on heart weight and heart weight/body weight ratio are also given in Table 1 . Despite the ascites, the body weight gain in the ADR group was significantly less. Treatment with adriamycin resulted in a significant decrease in heart weight and ratio of heart to body weight in the ADR group. In the PROB+ADR group, ratio of heart to body weight was not significantly different from the CONT and PROB groups. Heart weight in the PROB+ADR group was significantly higher than in the ADR group but was still lower than in the CONT and PROB groups.
Hemodynamic Studies ASP, ADP, LVSP, and LVEDP were recorded in all groups; these data are shown in Table 2 . There were significant changes in cardiac performance in the ADR group. LVEDP in both ADR and PROB+ADR groups was higher than values in the CONT and PROB groups; however, this value was relatively more increased in the ADR than the PROB+ADR group. LVSP was significantly decreased in the ADR group alone, whereas in the PROB+ADR group, it was no different from the CONT and PROB groups. There was no difference between CONT and treated groups with respect to ADP. ASP values were significantly lower in the ADR group compared with all other groups.
Morphological Studies
Electron microscopic analysis of left ventricular free wall was conducted on heart tissue excised from all four groups of rats. The morphological appearance of different subcellular structures, including mitochondria, sarcoplasmic reticulum, sarcomeres, myofibrils, and intercalated disks, in hearts from control and probucol groups were typical of normal cells. Morphological changes due to adriamycin treatment alone included disruption of several subcellular elements including loss of myofibrils, swelling of mitochondria, vacuolization of the cytoplasm, formation of lysosomal bodies, and dilation of the sarcotubular system (Fig 1A) . Mitochondrial injury in addition to the swelling of these organelles was also accompanied by disarrangement and disruption of cristae (Fig 1B) . Some of the electron-dense bodies showed lamellar inclusions (Fig 1B) . These structural changes are typical for adriamycin cardiomyopathy.2'12'15 The ultrastructure of hearts from the PROB+ADR group showed regular myofibrillar structure, maintained sarcotubular reticulum, and preserved mitochondria (Fig 2A) . At higher magnification, intramitochondrial details were quite normal, but some intracellular edema was noticeable around the mitochondria (Fig 2B) .
Antioxidant Enzymes and Lipid Peroxidation
Different antioxidant enzyme activities were examined in all groups; these data are shown in Table 3 . GSHPx activity in the ADR group was reduced by about 32% compared with the CONT group. In the PROB+ADR group, GSHPx activity was near control levels. Total SOD activity in the PROB and PROB+ADR groups was significantly higher than in the CONT and ADR groups. Catalase activity did not change in any group. The amount of lipid peroxidation was determined by evaluating myocardial MDA content; these data are also shown in Table 3 . MDA levels were almost the same in the CONT, PROB, and PROB+ADR groups, whereas in the ADR group alone the MDA content was significantly higher. Probucol in the plasma is transported predominantly by low-density, very-low-density, and high-density lipoproteins. 26 Oral administration of probucol at 1 g/d increases its level in the blood as well as the adipose tissue.27 However, there seems to be no absolute correlation between the plasma levels of probucol and the extent of cholesterol lowering.28 Although it is difficult to draw any parallel between the dosage used by us in rats (6x 10 mg/kg IP) and therapeutic dosage (2x 500 mg/d for 3 to 6 months), the probucol treatment protocol used in our study was well tolerated.
Probucol treatment in heterozygous familial hypercholesterolemia caused the regression of xanthomas, which did not correlate with the level of cholesterol reduction.29 Cholestyramine, another cholesterol-lowering drug, and probucol both sharply lowered the serum cholesterol levels in nonhuman primates, but only probucol caused regression of atherosclerotic lesions. 30 These observations clearly suggest that beneficial effects of probucol may be independent of cholesterol lowering. Because of the two phenolic groups in its molecular structure, probucol has been reported to be a strong antioxidant,31'32 and it appears that the protection offered by probucol in this study may involve antioxidant mechanisms. In this regard, adriamycin has been shown to promote the production of free radicals13.14; these toxic species are known to cause myocardial dysfunction.33 Data on lipid peroxidation are also in concert with this suggestion, inasmuch as probucol caused a significant attenuation in the adriamycininduced increase in MDA levels. The beneficial effect of probucol against restenosis after percutaneous transluminal coronary angioplasty has also been suggested to be due to its antioxidant properties. 34 In addition to its cholesterol-lowering and antioxidant properties, probucol may also have an effect on endogenous antioxidant enzyme activities. Probucol not only prevented adriamycin-induced decreases in GSHPx activity but also increased SOD activity. It is important to note that in the ADR group, there was a small although statistically not significant increase in the SOD activity. Probucol alone caused a 33% increase in SOD; however, in the PROB+ADR group, there may have been some synergistic effect, since the increase in SOD activity was about 88%. Thus, probucol clearly improves "endogenous antioxidant reserve," and the latter has been suggested to improve myocardial structure and function. 35 The mechanisms for an adriamycin-induced decrease in GSHPx and probucol-induced increase in antioxidants (GSHPx and SOD) are not clear. This study, however, clearly demonstrates that probucol may be providing protection by acting as an antioxidant as well as by promoting endogenous antioxidants.
In conclusion, it can be said that adriamycin cardiomyopathy is associated with an antioxidant deficit and that probucol treatment improves the antioxidant status of the heart. Improved cardiac function due to treatment with probucol may be related to the maintenance of the antioxidant status of the heart. Adriamycin, because of its histophilic nature, is cleared from the plasma and appears in the tissues within minutes. 36 Since treatments with PROB and adriamycin were 24 hours apart, it is unlikely that PROB influenced adriamycin absorption. Nevertheless, future studies are required to resolve two important questions: (1) What are the molecular mechanisms for these antioxidant changes; and (2) does this antioxidant protection also influence absorption, body distribution, and thus antitumor properties of the drug? It would also be of interest to examine these beneficial effects of PROB in a larger animal model.
